feed,title,long_url,short_url
Benzinga,Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests,https://benzinga.com/general/biotech/22/02/25388353/roche-expects-slower-fy22-sales-growth-on-lower-demand-for-covid-19-tests,https://bit.ly/3rxFcUN
Benzinga,"Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales",https://benzinga.com/general/biotech/22/02/25389519/merck-clocked-950m-sales-in-q4-from-covid-19-treatment-issues-fy22-sales,https://bit.ly/3ARKspa
